Induction Therapy

Comparative study closed early because significantly fewer kidney rejections seen with Thymoglobulin

Published in Immunotherapy Weekly, April 24th, 2002

SangStat announced that an ad hoc, independent data safety monitoring board (DSMB) has decided to close the company's comparative kidney transplant study early after an interim analysis revealed significantly fewer acute rejections in patients treated with Thymoglobulin [Anti-thymocyte Globulin, (Rabbit)] versus Simulect (basiliximab, Novartis).

The prospectively randomized, phase II comparative study examined the use of Thymoglobulin or Simulect as induction therapy in high-risk kidney transplants. Induction therapy is administered at the time of transplant to prevent future acute rejection of the transplanted organ. In the U.S., Thymoglobulin is indicated only for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Immunotherapy Weekly

Source: Immunotherapy Weekly (2002-04-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry